<DOC>
	<DOCNO>NCT01762462</DOCNO>
	<brief_summary>Primary Objective : To study effect mild moderate hepatic impairment pharmacokinetics SAR302503 . Secondary Objective : To assess tolerability SAR302503 give single dose 300 mg subject mild moderate hepatic impairment match subject normal hepatic function .</brief_summary>
	<brief_title>Open Label Pharmacokinetic Study SAR302503 Subjects With Hepatic Impairment</brief_title>
	<detailed_description>Study duration=17-35 day</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion criterion : Male female subject , 18 75 year age , inclusive . Body weight 50.0 115.0 kg , inclusive male , 40.0 100.0 kg , inclusive female , body mass index 18.0 34.9 kg/m2 , inclusive . Stable chronic liver disease ChildPugh classification score 5 9 assessed medical history , physical examination , laboratory value 12lead ECG without clinically significant abnormality Laboratory parameter within acceptable range subject hepatic impairment Using double contraception method Exclusion criterion : Uncontrolled clinically relevant cardiovascular , pulmonary , gastrointestinal , metabolic , hematological , neurological , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . Hepatocarcinoma . Acute hepatitis Any significant change chronic treatment medication within 14 day inclusion Concomitant treatment use drug herbal agent know least moderate inhibitor inducer CYP3A4 sensitive narrow therapeutic index substrate CYP3A4 Concomitant treatment gastric pH modify agent Positive result follow test : antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab ) . Positive result urine drug screen Positive alcohol test . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>